Table 1.
Demographic and clinical data at baseline (intention-to-treat population) n (%)
| MBST | Hybrid | P value | |
| Included in ITT analysis | 140 | 144 | - |
| Age, mean ± SD (yr) | 58.9 ± 12.8 | 58.8 ± 11.9 | 0.922 |
| Gender (male) | 58 (41.4) | 72 (50.0) | 0.155 |
| Current smoker | 8 (5.7) | 9 (6.3) | 0.849 |
| Alcohol drinking | 18 (12.9) | 15 (10.4) | 0.581 |
| Diabetes | 7 (5.0) | 6 (4.2) | 0.783 |
| Hypertension | 27 (19.3) | 20 (13.9) | 0.264 |
| Previous history of peptic ulcer | 19 (13.6) | 18 (12.5) | 0.537 |
| Endoscopic diagnosis | 0.783 | ||
| HPAG | 117 (83.6) | 136 (94.4) | |
| Gastric ulcer | 8 (5.7) | 6 (4.2) | |
| Duodenal ulcer | 5 (3.6) | 0 (0.0) | |
| Gastric and duodenal ulcer | 2 (1.4) | 2 (1.4) | |
| Adenoma | 8 (5.7) | 0 (0.0) | |
| Positive CLO test | 106 (75.7) | 116 (80.6) | 0.389 |
| H. pylori colonization | 0.234 | ||
| Negative | 7 (5.0) | 13 (9.0) | |
| Mild | 66 (47.1) | 65 (45.1) | |
| Moderate | 52 (37.1) | 43 (29.9) | |
| Marked | 15 (10.7) | 23 (16.0) | |
| Atrophic change | 11 (7.8) | 14 (9.8) | 0.122 |
| Intestinal metaplasia | 10 (7.2) | 16 (11.1) | 0.239 |
| Drop out | 4 (2.8) | 6 (4.1) | 0.285 |
| Noncompliance | 0 (0.0) | 0 (0.0) | |
| Follow-up loss | 4 (2.8) | 6 (4.1) | |
| Discontinued therapy | 0 (0.0) | 0 (0.0) | |
| due to adverse events |
MBST: 14-d moxifloxacin-based sequential therapy; Hybrid: 14-d hybrid therapy; ITT: Intention-to-treat; HPAG: Helicobacter pylori associated gastritis; CLO test: Rapid urease test; H. pylori: Helicobacter pylori.